DATABASE
Home
Database
Who We Are
What We Offer
Register
Sign In
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Name
Category
Actelion delivers strong first quarter 2013 results
News
Actelion erhält Zulassung für Epoprostenol "ACT" in Japan
News
Actelion Ltd.
Fund
Actelion mit starken Ergebnissen im ersten Quartal 2013
News
Actelion nominiert John J. Greisch zur Wahl in den Verwaltungsrat
News
Actelion obtains marketing approval for Epoprostenol "ACT" in Japan
News
Actelion Pharmaceuticals Russia Deploys Cloud-Based Mobile Intelligence™ to Leverage CRM Innovation in Pivotal Emerging Market
News
Actelion präsentiert anlässlich der 31. J.P. Morgan Healthcare Conference - Umsetzung der Strategie von Actelion
News
Actelion reicht Zulassungsantrag für Macitentan (Opsumit) bei der Europäischen Arzneimittel-Agentur (EMA) ein
News
Actelion submits the registration dossier for macitentan (Opsumit) to the European Medicines Agency (EMA)
News
Actelion to discuss nine months 2012 financial results
News
Actelion to present at the 31st Annual J.P. Morgan Healthcare Conference - Delivering on our strategy
News
Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland
News
Actelion's novel antibiotic cadazolid to move into Phase III clinical development in patients suffering from Clostridium difficile associated diarrhea
News
Actelion's ponesimod successful in mid-stage trial in patients with moderate to severe chronic plaque psoriasis - Ponesimod to proceed to Phase III cl
News
Actelions neuartiges Antibiotikum Cadazolid geht in Phase III der klinischen Entwicklung bei Patienten, die an Clostridium-difficile-assoziierter Diar
News
Actelions Ponesimod erfolgreich in fortgeschrittener Studie bei Patienten mit mittelschwerer bis schwerer Plaque-Psoriasis - Ponesimod geht in die Pha
News
Acteos
Fund
Acti-bail
Bank
Actielec Technologies
Fund
Actieninvest AG
Company
Actigep
Bank
Actinogen Limited
Fund
Actinver Casa De Bolsa Sa De Cv
Bank
Actinvest Sa
Bank
Page 130 of 1100